Apixaban Lowers Stroke Risk, but Increases Major Bleeding Risk in Subclinical AFib
Results of the ARTESIA trial suggest apixaban lowered stroke risk by 37% in subclinical atrial fibrillation versus aspirin, but increased major bleeding risk.
Stay updated with breaking news from Jeff Healey. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Results of the ARTESIA trial suggest apixaban lowered stroke risk by 37% in subclinical atrial fibrillation versus aspirin, but increased major bleeding risk.
(UPDATED) With an increase in major bleeding, too, there’s a question about whether the benefit is worth the risk.
Further analyses from the ARTESIA study and the previous NOAH-AFNET 6 trial are needed to try to identify groups where the benefit may outweigh the risk, researchers say.
Schooled in Stevie Ray Vaughan and Jimi Hendrix, the Canadian Strat sage teaches you some of his most raucous licks in this exclusive lesson
On October 25, 1968, Jimi Hendrix Experience released Electric Ladyland, their third and final album together.